Cadonilimab is efficacious in HER2-negative advanced-stage G/GEJ adenocarcinomas
- PMID: 39920434
- DOI: 10.1038/s41571-025-00998-z
Cadonilimab is efficacious in HER2-negative advanced-stage G/GEJ adenocarcinomas
References
Original article
-
- Shen, L. et al. First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. Nat. Med. https://doi.org/10.1038/s41591-024-03450-4 (2025) - DOI - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous